{"id":"W4225423587","doi":"10.1158/1078-0432.ccr-21-4115","title":"A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ipsen; Eisai; Rijksuniversiteit Groningen; Medical Research Council; G1 Therapeutics; Genentech; Janssen Scientific Affairs; Advanced Accelerator Applications; EMD Serono; Karyopharm Therapeutics; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Exelixis; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma; Celldex Therapeutics; Pfizer","keywords":"Durvalumab; Nivolumab; Renal cell carcinoma; Phases of clinical research; Kidney cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002045003,0.001601054,0.003041852,0.000361851,0.0004219139,0.001014167,0.0009223216,0.00131691,0.004077667],"category_scores_gemma":[0.001388894,0.000921151,0.001293857,0.0003616947,0.001311512,0.001047353,0.0004437078,0.002923273,0.0009760946],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000910249,"about_ca_system_score_gemma":0.001525822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005898004,"about_ca_topic_score_gemma":0.001666693,"domain_scores_codex":[0.9991946,0.0004708223,0.00003956617,0.0001288794,0.0000639024,0.0001023707],"domain_scores_gemma":[0.9989517,0.0002371898,0.0002136232,0.00009431357,0.00005835379,0.0004448339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.954179,0.02121003,0.001198167,0.0002674594,0.0007543635,0.00004925605,0.00007905323,0.0006253634,0.004768147,0.00009843522,0.0005901739,0.01618051],"study_design_scores_gemma":[0.8384328,0.1577014,0.001772668,0.00001244891,0.000206789,0.00004744794,0.00002301463,0.0006256375,0.0005383301,0.0001000562,0.0005249701,0.00001449004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992152,0.001643058,0.0005649276,0.0003376713,0.0002838582,0.003369556,0.0003840881,0.00006146432,0.001203417],"genre_scores_gemma":[0.9903049,0.001137939,0.001542825,0.0008038175,0.0003338383,0.003492197,0.0005800918,0.00001836004,0.001785883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004077667,"threshold_uncertainty_score":0.01364118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1397838591136135,"score_gpt":0.4579740759454266,"score_spread":0.318190216831813,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}